EX-4.2





 Exhibit 4.2 

Execution Version 
 RELAY
THERAPEUTICS, INC. 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 19, 2018, by
and among Relay Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Preferred Investor”, and the
stockholders that are now or in the future listed on Schedule B hereto, if any, which are referred to in this Agreement as the “Common Investor”, and together with the Preferred Investors, each an “Investor”
and collectively, the “Investors”. 
 RECITALS: 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Preferred Stock and/or
shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as of December 8,
2017, as amended to date (the “Prior Agreement”); 
 WHEREAS, the Existing Investors signatory hereto are holders of
a majority of the Registrable Securities (as defined in the Prior Agreement) of the Company and include at least one Major B Holder (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to
accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 
 WHEREAS,
certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement dated November 12, 2018 between the Company and such Investors (as the same may be amended or restated from time to time, the “Purchase
Agreement”), under which certain of the Company’s and such Investor’s obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding a majority of the Registrable
Securities (as defined in the Prior Agreement), including at least one Major B Holder (as defined in the Prior Agreement), and the Company. 

NOW, THEREFORE, the parties hereby agree as follows: 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who or which, directly
or indirectly, controls, is controlled by, or is under common control with such specified Person, including, without limitation, any partner, officer, director, member, manager or employee of such specified Person and any registered investment
company, venture capital or other investment fund now or hereafter existing that is controlled by or under common control with one or more general partners or managing members of, or is under common investment management or shares the same
management company or investment advisor with, such specified Person. Third Rock Ventures IV, L.P., Third Rock Ventures III, L.P. and the Company shall not be deemed to be Affiliates for the purposes of this Agreement. Notwithstanding anything to
the contrary in this Agreement, for purpose of this Agreement, D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., Inc., and/or Schrödinger, Inc. and/or any other Person directly or indirectly under
the control of D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., Inc. and/or Schrödinger, Inc. (including without limitation any investment fund managed and/or advised by any such entities or their
subsidiaries) shall not be deemed to be Affiliates of Picularium, LLC. 












 1.2    “Board of Directors” means the Company’s
Board of Directors. 
 1.3    “Business Day” means a day (i) other than Saturday or Sunday and
(ii) on which commercial banks are open for business in Boston, Massachusetts and San Francisco, California. 

1.4    “BVF” means Biotechnology Value Fund LP, together with its Affiliates. 

1.5    “Casdin” means Casdin Partners Master Fund, L.P. 

1.6    “Certificate of Incorporation” means the Company’s Third Amended and Restated Certificate of
Incorporation, as the same may be amended, restated or otherwise modified from time to time. 
 1.7    “Common
Stock” means shares of the Company’s common stock, par value $0.001 per share. 

1.8    “Competitor” means a Person engaged, directly or indirectly (including through any partnership,
limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in activities or a line of business that are directly or indirectly competitive with Company’s business as then conducted
or as then proposed to be conducted, but shall not include (i) any financial investment firm or collective investment vehicle that solely by virtue of its ownership (and/or its Affiliates’ ownership) of an equity interest that is less than
twenty percent (20%) of the outstanding equity in any Competitor and is held solely for investment purposes, (ii) GV 2017, L.P. or any of its affiliated funds, (iii) SoftBank, (iv) any of the LP Investors, (v) Casdin, or
(vi) Perceptive and its Affiliates. Notwithstanding the foregoing, for purposes of this definition, (i) D. E. Shaw Research, LLC shall not be deemed a Competitor unless D. E. Shaw Research, LLC exercises its rights under (and in accordance
with) Section 4.1(b)(ii) of the Collaboration Agreement dated August 17, 2016 by and between D. E. Shaw Research, LLC and the Company, as amended by Amendment No. 1 thereto, dated June 11, 2018, and Amendment No. 2 thereto,
dated September 29, 2018 (as the same may be further amended from time to time, the “Collaboration Agreement”), releasing D. E. Shaw Research, LLC from its exclusivity obligations with respect to a Category 1 Target (as defined
in the Collaboration Agreement), and (ii) Picularium, LLC shall not be deemed a Competitor unless D. E. Shaw Research, LLC is deemed to be a Competitor hereunder. For the avoidance of doubt, in no event shall Picularium, LLC be deemed a
Competitor by reason of any activities, operations or attributes of Schrödinger, Inc. and/or because of Picularium, LLC’s direct or indirect relationship to Schrödinger, Inc. 

1.9    “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto
may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged
untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or
Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

  
 2 













 1.10    “Deemed Liquidation Event” shall have the
meaning given to such term in the Certificate of Incorporation. 
 1.11    “Derivative Securities”
means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.12    “EcoR1” means EcoR1 Capital Fund, L.P., together with its Affiliates. 

1.13    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 1.14    “Excluded Registration” means (i) a registration
relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; or (iii) a registration on any form
that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities. 

1.15    “Form S-1” means such form under the Securities
Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.16    “Form S-3” means such form under the Securities
Act as in effect on the date hereof, any successor registration form under the Securities Act subsequently adopted by the SEC or any other registration form under the Securities Act adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.17    “GAAP” means
generally accepted accounting principles in the United States. 
 1.18    “Holder” means any holder of
Registrable Securities who is a party to this Agreement. 
 1.19    “Immediate Family Member” means a
child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including adoptive relationships, of a natural person referred to herein. 

  
 3 













 1.20    “Initiating Holders” means, collectively,
Holders who properly initiate a registration request under this Agreement. 
 1.21    “IPO” means the
Company’s first underwritten public offering of its Common Stock under the Securities Act. 
 1.22    “Key
Employee” means (i) any executive-level employee of the Company (including division director and Vice President level positions), and (ii) any employee of the Company or individual consultant engaged by the Company who either
alone or in concert with others develops, invents, programs or designs any Company Intellectual Property (as defined in the Purchase Agreement). For the avoidance of doubt, no employee of or consultant to D. E. Shaw Research, LLC or any other entity
directly or indirectly controlling or under the control of D. E. Shaw Research, LLC shall be, or shall be deemed to be, a Key Employee or an employee of the Company, except as the Company and D. E. Shaw Research, LLC may otherwise agree in a written
agreement executed by duly authorized officers or members of the Company and D. E. Shaw Research, LLC. 

1.23    “Major Investor” means (i) any Preferred Investor that, individually or together with such
Investor’s Affiliates, holds at least 4,000,000 shares of Registrable Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date of the
Purchase Agreement), (ii) Schrödinger, Inc., solely for purposes of Sections 3.1(a) through (c), for so long as it holds shares of Common Stock and (iii) each LP Investor (as defined below) for so long as such LP Investor
holds at least fifty percent (50%) of the shares of Series C Preferred Stock held by it immediately following the Closing (as defined in the Purchase Agreement). 

1.24    “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.25    “LP Investors” means, collectively, each of PH Investments, LLC, SCubed Capital, LLC, Sobrato
Family Holdings, LLC, Harvard Management Private Equity Corporation, Portland Magenta EP, LLC, Portland Magenta PIA, LLC and Fifth Avenue Private Equity 14 LLC. 

1.26    “Perceptive” means Perceptive Life Sciences Master Fund, Ltd. 

1.27    “Person” means any individual, firm, corporation, partnership, trust, joint venture, limited
liability company, association or other entity. 
 1.28    “Preferred Directors” means, collectively,
the Series A Director, the Series B Director and the Series C Director. 

  
 4 













 1.29    “Preferred Director Majority” means a majority
of the Preferred Directors then serving on the Board of Directors. 
 1.30    “Preferred Stock” means,
collectively, the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series C-1 Preferred Stock. 

1.31    “QPO” shall have the meaning set forth in the Certificate of Incorporation. 

1.32    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Preferred Stock, or (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Investors or acquired by the Investors after the
date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement
of, the shares referenced in clauses (i) and (ii) above; provided that, (A) in all cases, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to Section 6.1 shall cease to be Registrable Securities, and (B) for purposes of Section 2, any Registrable Securities for which registration rights have terminated pursuant to
Section 2.13 of this Agreement shall cease to be Registrable Securities. 

1.33    “Registrable Securities then outstanding” means the number of shares at a point in time
determined by adding the number of shares of outstanding Common Stock that are Registrable Securities at such time and the number of shares of Common Stock issuable (directly or indirectly) at such time pursuant to then exercisable and/or
convertible securities that are Registrable Securities. 
 1.34    “Restricted Securities” means the
securities of the Company required to bear the legend set forth in Section 2.12(b) hereof. 

1.35    “SEC” means the Securities and Exchange Commission. 

1.36    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act, or any successor
provisions. 
 1.37    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act,
or any successor provisions. 
 1.38    “Securities Act” means the Securities Act of 1933, as amended,
and the rules and regulations promulgated thereunder. 
 1.39    “Selling Expenses” means all
underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne
and paid by the Company as provided in Section 2.6. 

  
 5 













 1.40    “Series A Director” means the director of the
Company that the holders of record of the Series A Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation, exclusively and as a separate class. 

1.41    “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value
$0.001 per share. 
 1.42    “Series B Director” means the director of the Company that the holders of
record of the Series B Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation, exclusively and as a separate class. 

1.43    “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value
$0.001 per share. 
 1.44    “Series C Director” means the director of the Company that the holders of
record of the Series C Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation, exclusively and as a separate class. 

1.45    “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value
$0.001 per share. 
 1.46    “Series C-1 Preferred Stock” means
shares of the Company’s Series C-1 Preferred Stock, par value $0.001 per share. 

1.47    “SoftBank” means SoftBank Vision Fund, L.P. and its Affiliates. 

1.48    “Stockholders Agreement” means the Second Amended and Restated Stockholders Agreement dated as of
the date hereof, by and among the Company, the Investors, and Key Holders (as defined therein), as the same may be amended, restated or otherwise modified from time to time. 

2.    Registration Rights. The Company covenants and agrees as follows: 

2.1    Demand Registration. 

(a)    Form S-1 Demand. Beginning upon the earlier of (i) five (5)
years after the date of this Agreement or (ii) six (6) months after the effective date of the registration statement for the IPO, if the Company receives a request from Holders of at least a majority of the Registrable Securities then
outstanding that the Company file a Form S-1 registration statement with respect to at least a majority of the Registrable Securities then outstanding, having the anticipated aggregate offering amount
of at least $7.5 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and
(y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act
covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

  
 6 













 (b)    Form S-3 Demand.
If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that
the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering amount, net of Selling Expenses, of at least
$1.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within
forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. 
 (c)    Notwithstanding the
foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1(c) a certificate signed by the Company’s chief executive officer or other most senior executive officer
then in office stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as
such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company;
(ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange
Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty
(120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period, nor shall the Company invoke this right more than twice
in all periods; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during either one hundred twenty (120) day period other than an Excluded Registration. 

(d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a), (i) if it delivers notice to the Holders within thirty (30) days after any registration request of its intent to file a registration statement for a public offering within ninety (90) days; (ii)
during the period that is one hundred eighty (180) days after commencing a Company-initiated registration; (iii) after the Company has effected two (2) registrations pursuant to Section 2.1(a); or
(iv) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to
Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) if the Company has effected two (2) registrations
pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration (other than as a result of a
material adverse change to the Company), elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration
statement shall be counted as “effected” for purposes of this Section 2.1(d). 

  
 7 













 2.2    Company Registration. If the Company proposes to register
(including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in
an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall,
subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses
(other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3    Underwriting Requirements. 

(a)    If, pursuant to Section 2.1, the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the
Demand Notice. The underwriter(s) will be selected by the Board of Directors and shall be reasonably acceptable to the Initiating Holders holding a majority of the Registrable Securities held by the Initiating Holders. In such event, the right of
any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting
to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary
form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise the Initiating Holders in writing that marketing factors require a
limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting
shall be allocated among such Holders, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder, or in such other proportion as shall mutually be agreed to by all such
selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To
facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

  
 8 













 (b)    In connection with any offering involving an underwriting of
shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting
as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the
success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not
jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering
shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder (that such selling Holder requested to be registered) or in such other proportions as shall
mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares.
Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the
offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b)
concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate
Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to
such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c)    For purposes of Section 2.1, a registration shall not be counted as “effected”
if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a) and (b), less than the total number of Registrable Securities that Holders have requested to be included in such
registration statement are actually included. 
 2.4    Obligations of the Company. 

Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall,
as expeditiously as reasonably possible: 
 (a)    prepare and file with the SEC a registration statement with respect
to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred
twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-1 or Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable
SEC rules, such one hundred twenty (120) day period shall be extended for up to three (3) years, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

  
 9 













 (b)    prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 (c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  
 10 













 (i)    notify each selling Holder, promptly after the Company receives
notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 2.5    Furnish Information. It shall be
a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $60,000, of one counsel for the selling Holders (“Selling Holder Counsel”) selected by the Holders of a majority of the Registrable Securities, shall be borne and paid by the Company;
provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of
the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration),
unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be; provided
further that if, at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the
request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or
Section 2.1(b), as the case may be. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the
number of Registrable Securities registered on their behalf. 
 2.7    Delay of Registration. No Holder shall
have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 

  
 11 













 2.8    Indemnification. If any Registrable Securities are
included in a registration statement under this Section 2: 
 (a)    To the extent permitted
by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, Affiliates and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as
defined in the Securities Act) for each such Holder; and each Person, if any, who controls or is under common control with such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company
will pay to each such Holder, partner, member, officer, director, Affiliate, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any
claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any
such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such
registration. 
 (b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each
such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such
expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall any indemnity or contribution under this Section 2.8(b) or under
Section 2.8(d) exceed, in the aggregate, the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c)    Promptly after receipt by an indemnified party under this Section 2.8 of notice
of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
  

  
 12 













 (d)    To provide for just and equitable contribution to joint
liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such
Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of
such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8, when combined with the amounts paid or payable by such Holder pursuant to
Section 2.8, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

  
 13 













 (f)    Unless otherwise superseded by an underwriting agreement entered
into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement. 
 2.9    Reports
under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall
not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or
prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of
such securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) to demand registration of any securities held by such holder or prospective holder; provided that this limitation shall not
apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

  
 14 













 2.11    “Market Stand-off” Agreement. 
 Each Holder hereby agrees that, if required by the managing
underwriter, it will not, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty
(180) days) (the “Lock Up Period”), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the
registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described
in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, shall not apply to shares purchased in the IPO or after the IPO, and shall be applicable to the Holders only if all officers, directors, and stockholders individually
owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such
registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party
hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give
further effect thereto. The Company agrees to use its reasonable efforts to obtain the agreement of the managing underwriter to periodic early releases of portions of the securities subject to such lock-up
agreements upon the request of a Holder to such early release, provided that in the event of any early release, all Holders will be released on a pro rata basis from such agreements. Any discretionary waiver or termination of the restrictions of any
or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements; provided, however, that no such
pro-rata waiver or termination will be triggered in connection with a discretionary waiver or termination in connection with any primary and/or secondary follow-on
public offering of shares of Common Stock pursuant to a registration statement on Form S-1 (a “Follow-on Offering”) that is filed with the SEC during
the Lock Up Period so long as such Holder has been given the opportunity to participate in such Follow-on Offering on the same terms as any other equity holders participating in such Follow-on Offering. 
 2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause
any proposed purchaser, pledgee, or transferee of the Preferred Stock or the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

  
 15 













 (b)    Each certificate or instrument representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY
AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records
and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c)    The holder of each certificate or instrument representing Restricted Securities, by acceptance thereof, agrees to
comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering
the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or
transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory
to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge,
or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company
to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer
such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration provided that each transferee agrees in writing to be subject to the terms of this Section 2.12 or (y) in any transaction in compliance with SEC
Rule 144. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 

  
 16 













 2.13    Termination of Registration Rights. The right of any
Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b)    such time after the IPO as Rule 144 or another similar exemption under the Securities Act is available for the
sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c)    the fifth (5th) anniversary of the IPO. 

3.    Information. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor the required items listed
below, provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company. 

(a)    as soon as practicable, but in any event within forty-five (45) days after the end of each fiscal year of the
Company, unaudited statements of income and of cash flows for such fiscal year, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal year, all prepared in accordance with GAAP (except that such
financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(b)    as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the
Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited
and certified by independent public accountants of nationally recognized standing selected by the Company and approved by the Board of Directors, including the Preferred Director Majority; 

(c)    as soon as practicable but in any event within forty-five (45) days after the end of each quarter of each
fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with
GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

  
 17 













 (d)    as soon as practicable, but in any event within thirty
(30) days after the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance
with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e)    as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each
fiscal year of the Company and within thirty (30) days after a change in the Company’s fully diluted capitalization, or upon request by a Major Investor, a statement showing the number of shares of each class and series of capital stock
and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the
exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit each Major Investor to calculate their
respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct; 

(f)    as soon as practicable, but in any event within thirty (30) days before the end of each fiscal year, a budget
and business plan for the next fiscal year, forecasting the Company’s revenue, expenses, capital expenditures and cash position on a monthly basis (collectively, the “Budget”), approved by the Board of Directors, including the
Preferred Director Majority, and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(g)    as soon as practicable, but in any event within thirty (30) days upon receipt of a written request from a
Major Investor, unaudited monthly financial statements in a form reasonably agreed with such Major Investors; and 

(h)    such other information relating to the financial condition, business, prospects, or corporate affairs of the
Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company reasonably
determines in good faith to be a trade secret, confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company), or otherwise includes software or technology the release of which to the Major
Investor would require a specific license under applicable export control laws; or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

  
 18 













 Notwithstanding anything else in this Section 3.1 to the contrary, the Company may
cease providing the information set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if
it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at
such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

Notwithstanding anything to the contrary herein, in the event that Picularium, LLC is deemed to be a Competitor, for so long as it remains a Major Investor,
Picularium, LLC shall be entitled to receive the materials described in Sections 3.1(a), 3.1(b) and 3.1(e). 

3.2    Inspection. The Company shall permit each Major Investor (provided that such Major Investor is not a
Competitor of the Company as reasonably determined by the Board of Directors), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this
Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret, confidential information (unless covered by an enforceable confidentiality agreement, in a form
acceptable to the Company), otherwise includes software or technology the release of which to the Major Investor would require a specific license under export control laws; or the disclosure of which would adversely affect the attorney-client
privilege between the Company and its counsel. 
 3.3    Observer Rights. After CFIUS Clearance, as long
as SoftBank owns any Registrable Securities, the Company shall invite a representative of SoftBank to attend all scientific sessions of meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such
representative copies of all notices, minutes, consents, and other materials that it provides to its directors relating to such sessions at the same time and in the same manner as provided to such directors; provided, however, that
such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from
any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or result in a conflict of interest. 

3.4    Termination of Information and Observer Rights. The covenants set forth in Sections 3.1, 3.2
and 3.3 shall terminate and be of no further force or effect upon the earliest to occur of (i) immediately before, but subject to, the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event that, in the case of SoftBank, results in SoftBank receiving solely cash, publicly traded securities or some combination thereof in
connection with such Deemed Liquidation Event. 

  
 19 













 3.5    Confidentiality. Each Investor agrees that such Investor
will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of
the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by
such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach
of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, advisors and other professionals
(collectively, “Representatives”) to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor,
if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) in the ordinary course of business to any existing or prospective, direct or indirect, Affiliate of such Investor or any existing
or prospective, direct or indirect, investor in any fund or vehicle managed by such Investor or an Affiliate, or any partner, member, stockholder, or wholly owned subsidiary of such Investor and any Representatives, employees or Affiliates of any of
the foregoing, provided that such Investor informs any such recipient that such information is confidential and directs such recipient to maintain the confidentiality of such information; (iv) as may otherwise be required by law or securities
exchange regulations or at the request of a regulatory authority, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure; or (v) in the case
of SoftBank, and without limiting the foregoing to the following: (A) the manager and sub-advisers of SoftBank, (B) the general partner of SoftBank, (C) the committees of SoftBank Investment
Advisers (US) Inc. and SoftBank Investment Advisers (UK), Ltd., (D) SoftBank’s existing and prospective limited partners, and (E) existing and prospective lenders to SoftBank or its Affiliates. 

4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Section 4.1 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby
granted to it among itself and its Affiliates in such proportions as it deems appropriate, provided that each such Affiliate (x) is not a Competitor of the Company as reasonably determined by the Board of Directors, and
(y) agrees to enter into this Agreement and the Stockholders Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement. 

(a)    The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its
bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b)    By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor
may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all
shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total number of shares of Common
Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) (the “Pro Rata Amount”). At the expiration of such twenty (20) day period,
the Company shall promptly notify SoftBank of any other Major Investor’s failure to elect to purchase or acquire all of the shares available to such Major Investor. During the ten (10) day period commencing after the Company has given such
notice, SoftBank may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, some or all of the New Securities for which Major Investors were entitled to subscribe, but that were not
subscribed for by the Major Investors. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred twenty (120) days after the date that the Offer Notice is given and the
date of initial sale of New Securities pursuant to Section 4.1(c). 

  
 20 













 (c)    If fewer than all New Securities referred to in the Offer Notice
are elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b),
offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into
an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities
shall not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

(d)    The right of first offer in this Section 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Certificate of Incorporation), and (ii) shares of Common Stock issued in the IPO. 

(e)    The rights of the Major Investors to purchase New Securities under this Section 4.1 may
be modified or waived in accordance with Section 6.6. 
 (f)    Until CFIUS Clearance (as
defined in the Purchase Agreement) has been obtained, if SoftBank exercises its rights pursuant to this Section 4.1, the Company agrees to take all actions necessary to restructure the closing of any purchase by SoftBank of
New Securities (a “ROFO Closing”) to ensure that SoftBank receives securities in such ROFO Closing that have equivalent rights, preferences and privileges to, and are pari passu in all respects with, the New Securities, except with
such reduced voting rights as and to the extent necessary to ensure that all shares of voting securities owned by SoftBank after a ROFO Closing do not possess greater than 9.99% of the combined voting power of the Company’s outstanding voting
securities. To the extent the actions contemplated by this Subsection 4.1(f) result in any delay, the time periods set forth in this Section 4.1 shall be tolled by the amount of such delay. 

4.2    Termination. The covenants set forth in Section 4.1 shall terminate and be of no
further force or effect upon the earliest to occur of (i) immediately before, but subject to, the consummation of the QPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or (iii) upon a Deemed Liquidation Event. 

  
 21 













 5.    Additional Covenants. 

5.1    Insurance. Within 90 days after the date of this Agreement, the Company shall obtain from financially sound
and reputable insurers Directors and Officers Errors and Omissions insurance in an amount satisfactory to the Board of Directors, including the Preferred Director Majority, which amount shall not be less than $5,000,000. The Company will use
commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors, including the Preferred Director Majority, determines that such insurance should be discontinued. 

5.2    Employee Agreements. The Company will cause (a) each individual now or hereafter employed by it or by
any subsidiary (or engaged by the Company or any subsidiary as an individual consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement
and (b) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, or as otherwise permitted by law, substantially in the form approved by the Board of Directors, including the Preferred Director Majority.
In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the approval by the
Board of Directors, including the Preferred Director Majority. 
 5.3    Employee Vesting. Unless otherwise
approved by the Board of Directors, which approval shall include the Preferred Director Majority, all current and future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the
Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (a) vesting of shares, not faster than over a four (4) year period, with the first
twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal quarterly installments over the following three (3) years, and (b) a market stand-off provision substantially similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, including the Preferred Director Majority, the
Company shall retain (and not waive) a “right of first refusal” on employee transfers of shares of Common Stock until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment
of a holder of restricted stock. 
 5.4    Matters Requiring Investor Director Approval. So long as any shares of
Preferred Stock remain outstanding, the Company hereby covenants and agrees with each of the Preferred Investors that it shall not, without first obtaining the approval of the Board of Directors, which approval must include the affirmative vote of
the Preferred Director Majority; provided, however, that solely with respect to Subsection 5.4(j), prior to CFIUS clearance, the term “Preferred Director Majority” means any two of the following: the Series A Director, the Series B
Director (as defined below), and SoftBank: 
 (a)    make, or permit any subsidiary to make, any loan or advance to, or
own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

  
 22 













 (b)    make, or permit any subsidiary to make, any loan or advance to
any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the
Board of Directors; 
 (c)    guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or
indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d)    make any investment inconsistent with any investment policy approved by the Board of Directors; 

(e)    incur indebtedness in excess of $250,000 in the aggregate that is not covered by the Budget, other than trade
credit incurred in the ordinary course of business; 
 (f)    otherwise enter into or be a party to any transaction
with any director, officer or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; 

(g)    hire, terminate, or change the compensation of the executive officers, including approving any option grants or
stock awards to executive officers; 
 (h)    change the principal business of the Company, or enter into a new line of
business, or exit the existing line of business of the Company; 
 (i)    sell, assign, license, pledge or encumber
material technology or intellectual property, other than licenses granted in the ordinary course of business; or 

(j)    enter into any corporate strategic relationship involving the payment contribution or assignment by the Company or
to the Company of money or assets greater than $500,000. 
 5.5    Meetings of the Board of Directors;
Committees. Unless otherwise determined by the vote of at least a majority of the directors then in office, the Board of Directors shall meet at least four (4) times per year, and at least once per quarter, in accordance with an agreed-upon
schedule, unless otherwise agreed by a vote of the majority of directors of the Board of Directors, including the Preferred Director Majority. Each non-employee director shall be entitled in such person’s
discretion to be a member of any committee of the Board of Directors. 
 5.6    Classified Board. The Company
shall take all necessary and desirable actions to ensure that, (a) in connection with the IPO, the Certificate of Incorporation in effect upon consummation of the IPO provides that the Board of Directors shall be classified into three classes
of directors with staggered three-year terms, (b) the person then designated for election to the Board of Director by SoftBank (the “SoftBank Director”), if any, shall, following the consummation of the IPO, serve in the class
of directors to be elected at the Company’s first annual meeting of stockholders following the IPO (the “First Annual Meeting”), and (c) the SoftBank Director shall be nominated for
re-election to the Board of Directors at the First Annual Meeting (or action by written consent of stockholders pursuant to which directors of such class are to be elected). The Company shall use its
reasonable efforts to cause the election of the SoftBank Director to the Board of Directors and will provide the same level of support as is used and/or provided for the other director nominees of the Company with respect to the First Annual Meeting
(or action by written consent of stockholders pursuant to which directors of such class are to be elected). 

  
 23 













 5.7    Successor Indemnification. If the Company or any of
its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the
Company’s By-laws, the Certificate of Incorporation, or elsewhere, as the case may be. 

5.8    Board Expenses. The Company shall reimburse the non-employee
directors for all reasonable out-of-pocket expenses incurred (consistent with the Company’s policies) in connection with their role as a director of the Company.

 5.9    Budget Matters. The Board of Directors, including the Preferred Director Majority, shall approve a
comprehensive operating budget forecasting the Company’s revenues, expenses, capital expenditures and cash position on a month-to-month basis for the upcoming
fiscal year prior to the end of each fiscal year. 
 5.10    Directors’ Liability and
Indemnification. 
 (a)    The Certificate of Incorporation and By-laws (as
such By-laws of the Company may be amended from time to time) shall provide (i) for limitation of the liability of directors to the maximum extent permitted by law, and (ii) for indemnification of
directors for acts on behalf of the Company to the maximum extent permitted by law. In the event any suit is filed or claim is asserted against a director or former director of the Company as a result of such director’s or former
director’s service on the Board of Directors, the Company will provide such director or former director access to all records and files of the Company as he or she may reasonably request in defending against or preparing to defend against any
such suit or claim. 
 (b)    The Company hereby acknowledges that one or more of the directors nominated by holders of
Preferred Stock may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby
agrees (i) that it is the indemnitor of first resort (i.e., its obligations to any such director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities
incurred by such director are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by such director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in
settlement by or on behalf of any such director to the extent legally permitted and as required by the Certificate of Incorporation or By-laws of the Company (or any agreement between the Company and such
director), without regard to any rights such director may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for
contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such director with respect to any claim for which such director has
sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such director
against the Company. Such directors and the Fund Indemnitors are intended third-party beneficiaries of this Subsection 5.10(b) and shall have the right, power and authority to enforce the provisions of this Subsection 5.10(b) as though
they were a party to this Agreement. 

  
 24 













 5.11    Right to Conduct Activities. The Company hereby agrees
and acknowledges that each of Third Rock Ventures III, L.P., Third Rock Ventures IV, L.P., Picularium, LLC, Casdin, GV 2017, L.P., EcoR1, BVF, each LP Investor, Boxer Capital, LLC, Perceptive and SoftBank (in each case, together with its Affiliates)
(each, an “Investing Entity”) invests in or may hereafter invest in one or more other portfolio companies (“PortCos”), some of which may be deemed competitive with the Company’s business (as currently conducted
or as currently proposed to be conducted). The Company hereby agrees that (a) no Investing Entity shall be deemed to be a Competitor of the Company in respect of any investment such Investing Entity makes in any PortCo, and (b) to the
extent permitted under applicable law, no Investing Entity shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Investing Entity in any entity competitive with the Company, or (ii) actions
taken by any partner, officer or other representative of such Investing Entity to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether
or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential
information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.12    Termination of Covenants. The covenants set forth in this Section 5, except for
Sections 5.6, 5.7, and 5.10, shall terminate and be of no further force or effect upon the earliest to occur of (i) immediately before but subject to the consummation of a QPO or (ii) when the Company first becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event. 

6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate, member, retired partner, retired member or stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an
individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends,
combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate, limited partner, retired partner, member,
retired member, or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and
with those of the transferring Holder and its Affiliates; provided further that all transferees who would not qualify individually for assignment of rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties, including without limitation, the Investor’s Affiliates. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 25 













 6.2    Governing Law. This Agreement shall be governed by and
construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3    Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature, email signature, or other form of electronic transmission. 

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 6.5    Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent, if sent by confirmed electronic mail or facsimile and
sent during normal business hours of the recipient, and if not so confirmed, then on the next Business Day; (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one (1)
Business Day after the Business Day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at their addresses as set forth on Schedule A and Schedule B hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number,
or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy, which shall not constitute notice, shall also be sent to Mitchell S. Bloom and
William D. Collins at Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210. 

  
 26 













 6.6    Amendments and Waivers. Any term of this Agreement,
including without limitation Section 4.1, may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the
written consent of the Company and the holders of a majority of the Registrable Securities then outstanding plus, prior to CFIUS Clearance (as defined in the Purchase Agreement), SoftBank; provided that the Company may in its sole
discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c)
shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing: 

(a)    subject to clause (c) below, this Agreement may not be amended or terminated and the observance of any term
hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by
agreement with the Company, purchase securities in such transaction); 
 (b)    none of Sections 1.1,
1.8, 1.22, and 3.1 (in each case, as it relates to the sentence(s) addressing Picularium, LLC and/or D. E. Shaw Research, LLC), or this clause (b) may be amended or waived without the express written consent or affirmative
vote of Picularium, LLC; 
 (c)    this clause (c) and Sections 1.1, 1.8, 1.27, 1.30,
2.11, 3, 4, 5.1, 5.4, 5.5, 5.6, 5.7, 5.10, 5.11, 5.12, and the definitions of “Competitor” and “SoftBank” may not be amended or waived (either generally
or in a particular instance and either retroactively or prospectively) in a manner adverse to SoftBank without the written consent of SoftBank; and 

(d)    this clause (d), the definition of “Competitor” in Section 1 and the
definition of “Investing Entity” in Section 5.11 of this Agreement may not be amended or waived in a manner adverse to an Investor named in the definition of “Competitor” without the written consent of
such Investor. 
 The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent
in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has
consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 


  
 27 













 6.7    Severability. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8    Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated Person may apportion such rights as among themselves in any manner they deem appropriate. 

6.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if after the date hereof
the Company issues additional shares of the Preferred Stock to a Person who is not already a party to this Agreement (any such person, a “New Investor”), as a condition to the issuance of such shares the Company shall require that
such New Investor become a party to this Agreement by executing and delivering a counterpart signature page or joinder agreement to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or
consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.
Schedule A or Schedule B to this Agreement shall be updated, as applicable, to reflect the issuance of Preferred Stock and Common Stock, respectively, to a New Investor. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness
of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11    Delays or Omissions. Except as set forth in Section 2.1(c) (with respect to the
Company’s failure to object promptly to a transfer), no delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any
such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of
any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 6.12    Dispute Resolution. 

(a)    Any and all disputes, claims, or controversies arising out of or relating to this Agreement, or the breach,
termination or validity thereof or the scope or applicability of this Agreement to arbitrate (each, a “Dispute”), will be finally resolved in accordance with the procedures set forth in this Section 6.12
and these procedures will be the sole and exclusive process for the resolution of such Disputes. 

  
 28 













 (b)    Any Dispute will be finally settled by arbitration administered
by the American Arbitration Association (“AAA”) in accordance with its Commercial Arbitration Rules then in effect, except as modified herein. 

(c)    The number of arbitrators will be three, one of whom will be appointed by each of the Company, on the one hand,
and the Investor(s) party to such Dispute, on the other hand, and the third of whom will be selected by mutual agreement of the Company and such Investor(s) party to such Dispute, within ten (10) Business Days after the selection of the second
arbitrator and thereafter by the AAA. The place of arbitration shall be New York, New York. Any arbitrators appointed by the AAA shall be selected from the American Arbitration Association’s “National Panel” and shall have extensive
commercial experience that is sufficient given the nature and complexity of this Agreement and the transactions contemplated thereby, and if practicable, shall have experience relating to private companies or disputes related to private company
investments. 
 (d)    The arbitrators will have no authority (1) to make any ruling, finding, or award that does
not conform to the terms and conditions of this Agreement or (2) to grant a remedy of specific performance. The provisions of the Federal Arbitration Act (9 U.S.C. § 1 et seq.) shall apply to any arbitration and award issued hereunder.

 (e)    The award of the arbitrators, which shall be issued, if practicable, within six months of the appointment of
the arbitrators, or as soon thereafter as practicable, shall be final and binding. Judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 

(f)    Any party may apply to a court of competent jurisdiction solely (1) to seek injunctive relief in order to
compel arbitration or to maintain the status quo and prevent irreparable harm until such time as an arbitration panel is appointed or the controversy is otherwise resolved and/or (2) to enforce an arbitration award, and for no other purpose.

 (g)    The arbitral tribunal and the AAA and the parties shall agree to keep confidential and not disclose
information concerning (1) the existence of an arbitration, (2) any documentary or other evidence given by a party or witness in the arbitration, or (3) the arbitration award, provided that a party may make such disclosures as are
necessary to comply with any applicable law or the request of any governmental authority after notifying the other party in advance, or as may be required to enforce this agreement to arbitrate or any arbitral award. 

(h)    EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY IN RESPECT OF ANY ACTION
PERMITTED UNDER SECTION 6.12(f) HEREIN. 
 (i)    The prevailing party(ies) shall be entitled to reasonable
attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party(ies) may be entitled. 

[Remainder of Page Intentionally Left Blank] 

  
 29 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	RELAY THERAPEUTICS, INC.
		
	By:	 	/s/ Sanjiv Patel
	Name: Sanjiv Patel
	Title: President and Chief Executive Officer



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 SOFTBANK VISION FUND (AIV M2) L.P.

	
	By: SB Investment Advisers (UK) Limited, acting as Manager of SoftBank Vision Fund (AIV M2) L.P.
		
	By:	 	/s/ Rajeev Misra
	Name: Rajeev Misra
	Title: Director



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	THIRD ROCK VENTURES III, L.P.
	
	By: Third Rock Ventures GP III, L.P., its general partner
	By: TRV GP III, LLC, its general partner
		
	By:	 	/s/ Kevin Gillis
	Name: Kevin Gillis
	Title: Chief Financial Officer
	Address: 29 Newbury Street #301
	Boston, MA 02116
	
	THIRD ROCK VENTURES IV, L.P.
	
	By: Third Rock Ventures GP IV, L.P., its general partner
	By: TRV GP IV, LLC, its general partner
		
	By:	 	/s/ Kevin Gillis
	Name: Kevin Gillis
	Title: Chief Financial Officer
	Address: 29 Newbury Street #301
	Boston, MA 02116



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ALEXANDRIA VENTURE INVESTMENTS, LLC,
	A Delaware limited liability company
	
	By: Alexandria Real Estate Equities, Inc., a Maryland corporation, managing member
		
	By:	 	/s/ Aaron Jacobson
	Name: Aaron Jacobson
	Title: SVP, Venture Counsel
	
	Address: 385 E. Colorado Blvd., Suite 299 Pasadena, CA 91101



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PICULARIUM, LLC,
	A Delaware limited liability company
		
	By:	 	/s/ Charles Ardai
	Name: Charles Ardai
	Title: Authorized Signatory
	
	Address: c/o D. E. Shaw Research, LLC
	120 West 45th Street, 39th Floor
	New York, NY 10036



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE FUND, LP
		
	By:	 	/s/ Mark Lampert
	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself GP Biotechnology Value Fund, L.P.
	
	Address: 44 Montgomery Street, 40th Floor, San Francisco, CA 94104



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE FUND II, LP
		
	By:	 	/s/ Mark Lampert
	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself GP Biotechnology Value Fund, L.P.
	
	Address: 44 Montgomery Street, 40th Floor, San Francisco, CA 94104



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE TRADING FUND OS, LP
		
	By:	 	/s/ Mark Lampert
	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself sole Member BVF Partners OS, Ltd., itself GP Biotechnology Value Trading Fund OS, L.P.
	
	Address: PO Box 309 Ugland House, Grand Cayman, KY1-1104, Cayman Islands



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	INVESTMENT 10, LLC
		
	By:	 	/s/ Mark Lampert
	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself Attorney-in-fact mInvestment 10, L.L.C.
	
	Address: 90 N Michigan Ave Suite 1100, Chicago, IL 60611



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MSI SPV LLC
		
	By:	 	/s/ Mark Lampert
	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself Attorney-In-Fact MSI BVF SPV, LLC
	
	 Address: c/o Magnitude Capital LLC

	200 Park Avenue, 56th Floor, New York, NY 10166



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CASDIN PARTNERS MASTER FUND, L.P.
	
	By: Casdin Partners GP, LLC, its General Partner
		
	By:	 	/s/ Eli Casdin
	Name: Eli Casdin
	Title: Managing Member
	
	 Address: 1350 Avenue of the Americas Suite 2600

New York, NY 10019





  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CASDIN VENTURE OPPORTUNITIES FUND, L.P.
	
	By: Casdin Venture Opportunities Fund GP, LLC, its General Partner
		
	By:	 	/s/ Eli Casdin
	Name: Eli Casdin
	Title: Managing Member
	
	Address: 1350 Avenue of the Americas Suite 2600
	New York, NY 10019



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ECOR1 CAPITAL FUND, L.P.
	
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	/s/ Oleg Nodelman
	Name: Oleg Nodelman
	Title: Managing Director
	
	Address: 409 Illinois Street
	San Francisco, CA 94158
	
	ECOR1 CAPITAL FUND QUALIFIED, L.P.
	
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	/s/ Oleg Nodelman
	Name: Oleg Nodelman
	Title: Managing Director
	
	Address: 409 Illinois Street
	San Francisco, CA 94158



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	GV 2017, L.P.
	By: GV 2017 GP, L.P., its General Partner
	By: GV 2017 GP, L.L.C., its General Partner
		
	By:	 	/s/ Daphne M. Chang
	Name: Daphne M. Chang
	Title: Authorized Signatory
	
	Attn: GV Legal Department
	1600 Amphitheatre Parkway
	Mountain View, CA 94043
	Email: notice@gv.com



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FORESITE CAPITAL FUND IV, L.P.
	
	By: Foresite Capital Management IV, LLC
	Its: General Partner
		
	By:	 	/s/ Dennis D. Ryan
	Name:	 	Dennis D. Ryan
	Title:	 	Chief Financial Officer



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
		
	By:	 	/s/ James A. Mannix
	Name: James A. Mannix
	Title: COO
	
	Address: c/o Perceptive Advisors, LLC
	51 Astor Place, 10th Floor
	New York, NY 1003



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BOXER CAPITAL, LLC
		
	By:	 	/s/ Aaron Davis
	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SECTION 32 FUND 1, LP
	
	By: Section 32 GP 1, LLC, its general partner
		
	By:	 	/s/ Jennifer L. Kercher
	Name: Jennifer L. Kercher
	Title: Chief Operating Officer
	
	Address: c/o Section 32 LLC
	171 Main Street, #671
	Los Altos, CA 94022



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	QUAKER HEALTH, LLC
		
	By:	 	/s/ Nathaniel S. Turner
	Name: Nathaniel S. Turner
	Title: Co-President
	
	Address: 139 Reade Street, Apt. 5A
	New York, NY 10013



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PH INVESTMENTS, LLC
		
	By:	 	/s/ Benjamin A. Gomez
	Name: Benjamin A. Gomez
	Title: Managing Director



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SCUBED CAPITAL, LLC
		
	By:	 	/s/ Mark Stevens
	Name: Mark Stevens
	Title: Managing Partner



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SOBRATO CAPITAL,
	a DBA of Sobrato Family Holdings, LLC,
	a California limited liability company
		
	By:	 	/s/ Matthew W. Sonsini
	Name: Matthew W. Sonsini
	Title: Chief Executive Officer, on behalf of Sobrato Family Holdings LLC



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HARVARD MANAGEMENT PRIVATE EQUITY CORPORATION
		
	By:	 	/s/ Elise McDonald
	Name: Elise McDonald
	Title: Authorized Signatory
		
	By:	 	/s/ Kathryn I. Murtagh
	Name: Kathryn I. Murtagh
	Title: Authorized Signatory



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PORTLAND INVESTMENT – EP, LLC
		
	By:	 	/s/ David B. Weden
	Name: David B. Weden, III
	Title: Corporate Director, Investment Operations



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PORTLAND INVESTMENT – PIA, LLC
	By: Partners HealthCare System Pooled Investment Accounts, LLC, its Managing Member
		
	By:	 	/s/ David B. Weden
	Name: David B. Weden, III
	Title: Corporate Director, Investment Operations



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIFTH AVENUE PRIVATE EQUITY 15 LLC
		
	By:	 	/s/ Charles D. Bryceland
	Name: Charles D. Bryceland
	Title: Authorized Signatory



  
 [Signature Page to
Second Amended and Restated Investors’ Rights Agreement] 













 SCHEDULE A 

Name and Contact of Preferred Investors 

THIRD ROCK VENTURES III, L.P. 
 29 Newbury Street; 3rd Floor 
 Boston, MA 02116 

Phone: (617)585-2000 

Fax: (617) 859-2891 

http://www.thirdrockventures.com 
 THIRD ROCK VENTURES IV,
L.P. 
 29 Newbury Street; 3rd Floor 

Boston, MA 02116 
 Phone:
(617)585-2000 
 Fax: (617) 859-2891 

http://www.thirdrockventures.com 
 ALEXANDRIA VENTURE
INVESTMENTS, LLC  
 285 E. Colorado Blvd., Suite 299 

Pasadena, CA 91101 
 PICULARIUM, LLC 

c/o D. E. Shaw Research, LLC 
 120 West 45th Street, 39th Floor

 New York, NY 10036 
 With a copy (which shall not
constitute notice) to: 
 Charles Ardai 
 D. E. Shaw
Research, LLC 
 120 West 45th Street, 39th Floor 
 New York, NY
10036 
 and to: 
 Wilmer Cutler Pickering Hale and Dorr
LLP 
 60 State Street 
 Boston, MA 02109 

Mark Murcko 
 520 Marshall Street 

Holliston, MA 01746 












 BIOTECHNOLOGY VALUE FUND, LP 

One Sansome Street 30th Floor 
 San Francisco, CA 94104 

BIOTECHNOLOGY VALUE FUND II, LP 
 One Sansome Street 30th
Floor 
 San Francisco, CA 94104 
 BIOTECHNOLOGY VALUE
TRADING FUND OS, LP 
 PO Box 309 Ugland House 
 Grand
Cayman, KY1-1104 
 Cayman Islands 

INVESTMENT 10, LLC 
 900 N Michigan Ave Suite 1100 

Chicago IL 60611 
 MSI SPV LLC 

c/o Magnitude Capital, LLC 
 200 Park Ave, 56th Floor 

New York, NY 10166 
 ECOR1 CAPITAL FUND, L.P. 

409 Illinois Street 
 San Francisco, CA 94158 

ECOR1 CAPITAL FUND QUALIFIED, L.P. 
 409 Illinois Street

 San Francisco, CA 94158 
 CASDIN PARTNERS MASTER FUND,
L.P. 
 1350 6th Avenue Suite 2600 
 New York, NY 10019 

CASDIN VNTURE OPPORTUNITIES FUND, L.P. 
 1350 6th Avenue
Suite 2600 
 New York, NY 10019 
 GV 2017, L.P. 

Attn: GV Legal Department 
 1600 Amphitheatre Parkway 

Mountain View, CA 94043 












 SOFTBANK VISION FUND (AIV M2) L.P. 

c/o SB Investment Advisers (UK) Limited 
 69 Grosvenor Street 

London, W1K 3JP 
 Attn: Legal Department 

- and - 
 c/o SB Investment Advisers (US), Inc. 

1 Circle Star Way, 3F 
 San Carols, CA 94070 

Attn: Legal Department 
 A copy (which shall not constitute
notice) shall also be sent to: 
 Cooley LLP 
 3175 Hanover
Street 
 Palo Alto, CA 94304 
 Attn: Matthew S. Bartus 

Boxer Capital, LLC 
 11682 El Camino Real, Suite 320 

San Diego, CA 92130 
 QUAKER HEALTH LLC 

139 Reade Street, Apt. 5A 
 New York, NY 10013 

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD. 
 c/o
Perceptive Advisors, LLC 
 51 Astor Place, 10th Floor 

New York, NY 10003 
 - and – 

Tannenbaum Helpern Syracuse & Hirschtritt LLP 
 900
Third Ave. 
 New York NY 10022 












 FORESITE CAPITAL FUND IV, L.P. 

600 Montgomery Street 
 Suite 4500 

San Francisco, CA 94111 
 SECTION 32 FUND 1, LP 

c/o Section 32 LLC 
 171 Main Street, #671 

Los Altos, CA 94022 
 PH Investments, LLC 

Pilot House, Lewis Wharf 
 Boston, MA 02110 

SCubed Capital, LLC 
 2061 Avy Avenue 

Menlo Park, CA 94025 
 Sobrato Capital 

Sobrato Family Holdings, LLC 
 10600 N. De Anza Blvd., Suite 200

 Cupertino, CA 95014 
 Phone:
408-446-0700 
 Harvard Management Private Equity Corporation 

Harvard Management Private Equity Corporation 
 600 Atlantic
Avenue 
 Boston, MA 02210 












 Portland Investment – EP, LLC 

101 Merrimac St., 8th Floor 
 Boston, MA 02114 

Portland Investment – PIA, LLC 
 101 Merrimac St.,
8th Floor 
 Boston, MA 02114 
 Fifth Avenue Private Equity
15 LLC 
 Bessemer Trust Company, N.A. 
 630 Fifth Avenue

 New York, NY 10111 












 SCHEDULE B 

Name and Contact of Common Investor 

SCHRÖDINGER, INC. 
 120 West 45th Street, 17th Floor 
 New York, New York 10036 












 RELAY THERAPEUTICS, INC. 

AMENDMENT TO INVESTORS’ RIGHTS AGREEMENT 

This Amendment to that certain Second Amended and Restated Investors’ Rights Agreement, dated December 19, 2018 (the
“Agreement”) by and among Relay Therapeutics, Inc. (the “Company”) and the investors listed on Schedule A thereto (the “Investors”), is made as of June 26, 2020, by and among the Company and
the undersigned Investors (this “Amendment”). All capitalized terms used but not defined herein shall have the meanings as defined in the Agreement. 

WHEREAS, the Company has entered into the Agreement with the Investors, and pursuant to Section 6.6 of the Agreement,
provisions of the Agreement may be amended only by written instrument executed by the Company and the holders of a majority of the Registerable Securities then outstanding (the “Requisite Holders”); and 

WHEREAS, the undersigned parties constitute the Requisite Holders and desire to amend certain provisions of the Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements contained herein, the Company and the Requisite Holders, on behalf of
all Investors, respectively, agree as follows: 
 1. Amendment. Section 5.6 of the Agreement is hereby amended and restated to
read as follows: 
 “5.6 Classified Board. The Company shall take all necessary and desirable actions to ensure that, (a) in
connection with the IPO, the Certificate of Incorporation in effect upon consummation of the IPO provides that the Board of Directors shall be classified into three classes of directors with staggered three-year terms, (b) the person then
designated for election to the Board of Director by SoftBank (the “SoftBank Director”), if any, shall, following the consummation of the IPO, serve in the class of directors to be elected at the Company’s
third annual meeting of stockholders following the IPO (the “Third Annual Meeting”), and (c) the SoftBank Director shall be nominated for re-election to the Board of Directors at
the Third Annual Meeting (or action by written consent of stockholders pursuant to which directors of such class are to be elected). The Company shall use its reasonable efforts to cause the election of the SoftBank Director to the Board of
Directors and will provide the same level of support as is used and/or provided for the other director nominees of the Company with respect to the Third Annual Meeting (or action by written consent of stockholders pursuant to which directors of such
class are to be elected).” 
 2. Governing Law. This Amendment and any controversy arising out of or relating to this Amendment
shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

3. Miscellaneous. This Amendment may not be altered, amended or modified in any way unless done in accordance with Section 6.6 of
the Agreement. To the extent not expressly amended hereby, the Agreement remains in full force and effect. This Amendment may be executed and delivered by facsimile or electronic signature and in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. If one or more provisions of this Amendment are held to be unenforceable under applicable law, such provision shall be excluded from this
Amendment and the balance of the Amendment shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. This Amendment, together with the Agreement (to the extent not amended hereby) and all
exhibits thereto and references therein, constitute the entire agreement among the parties and shall supersede any and all previous contracts, arrangements or understandings between the parties with respect to the subject matter herein. This
Amendment shall automatically terminate upon the expiration of the Term. 
 [Signature Page Follows] 

  
 1 













 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day
and year first above written. 
  

			
	COMPANY:
	
	RELAY THERAPEUTICS, INC.
		
	By:	 	 /s/ Sanjiv K. Patel

	Name:	 	Sanjiv K. Patel
	Title:	 	President and Chief Executive Officer


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	SVF Pauling (Cayman) Limited
		
	By:	 	 /s/ Karen Ellerbe

	Name:	 	Karen Ellerbe
	Title:	 	Director


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	BIOTECHNOLOGY VALUE FUND, L.P.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.
	
	BIOTECHNOLOGY VALUE FUND II, L.P.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.
	
	BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners, L.P., itself Sole Member BVF Partners OS Ltd, itself GP Biotechnology Value Trading Fund OS, L.P.


 [Signature Page to IRA Amendment] 












 
			
	MSI BVF SPV L.L.C.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners L.P., itself Attorney-In-Fact MSI BVF SPV LLC
	
	INVESTMENT 10, L.L.C.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., GP BVF Partners L.P., itself Attorney-In-Fact Investment 10, L.L.C.


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	THIRD ROCK VENTURES III, L.P.
	
	By: Third Rock Ventures GP III, L.P., its general partner
	By: TRV GP III, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

	Name: Kevin Gillis
	Title: Partner / COO
	
	Address: 29 Newbury Street #301
	Boston, MA 02116
	
	THIRD ROCK VENTURES IV, L.P.
	
	By: Third Rock Ventures GP IV, L.P., its general partner
	By: TRV GP IV, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

	Name: Kevin Gillis
	Title: Partner / COO


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	GV 2017, L.P.
	By: GV 2017 GP, L.P., its General Partner
	By: GV 2017 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name: Daphne M. Chang
	Title: Authorized Signatory


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
first above written. 
  

			
	INVESTORS:
	
	ALEXANDRIA VENTURE INVESTMENTS, LLC,
	A Delaware limited liability company
	
	By: Alexandria Real Estate Equities, Inc., a Maryland Company, managing member
		
	By:	 	 /s/ Aaron Jacobson

	Name:	 	Aaron Jacobson
	Title:	 	SVP - Venture Counsel


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	CASDIN PARTNERS MASTER FUND, L.P.
	
	By: Casdin Partners GP, LLC its General Partner
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Member
	
	CASDIN VENTURE OPPORTUNITIES FUND, L.P.
	
	By: Casdin Venture Opportunities Fund GP, LLC its General Partner
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Member


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	ECOR1 CAPITAL FUND, L.P.
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name: Oleg Nodelman,
	Title: Managing Director
	
	ECOR1 CAPITAL FUND QUALIFIED, L.P.
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name: Oleg Nodelman,
	Title: Managing Director


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	PICULARIUM, LLC,
	A Delaware limited liability company
	
	By: D. E. Shaw Research, LLC, its Manager
		
	By:	 	 /s/ Charles Ardai

	Name: Charles Ardai
	Title: Authorized Signatory


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	FORESITE CAPITAL FUND IV, L.P.
	
	By: Foresite Capital Management IV, LLC
	Its: General Partner
		
	By:	 	 /s/ Dennis D. Ryan

	Name: Dennis D. Ryan
	Title: Chief Financial Officer


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
		
	By:	 	 /s/ James H. Mannix

	Name: James H. Mannix
	Title: Coo


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	PH INVESTMENTS, LLC
		
	By:	 	 /s/ Mindy Barber

	Name: Mindy Barber
	Title: Managing Director


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	SCUBED CAPITAL, LLC
		
	By:	 	 /s/ Mark Stevens

	Name: Mark Stevens
	Title: Managing Partner


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	 SOBRATO CAPITAL,
 a DBA of
Sobrato Family Holdings, LLC,
 a California limited liability company

		
	By:	 	 /s/ Matthew W. Sonsini

	Name: Matthew W. Sonsini
	Title: Chief Executive Officer, on behalf of Sobrato Family Holdings LLC


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	HARVARD MANAGEMENT PRIVATE EQUITY COMPANY
		
	By:	 	 /s/ Richard Slocum

	Name: Richard Slocum
	Title: Authorized Signatory
		
	By:	 	 /s/ Kathryn Murtagh

	Name: Kathryn Murtagh
	Title: Authorized Signatory


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	BOXER CAPITAL, LLC
		
	By:	 	 /s/ Aaron Davis

	Name: Aaron Davis
	Title: Chief Executive Officer


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	PORTLAND INVESTMENT – EP, LLC
		
	By:	 	 /s/ David B. Weden, III

	Name: David B. Weden, III
	Title: Corporate Director, Investment Operations


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	 PORTLAND INVESTMENT – PIA, LLC

By: Partners HealthCare System Pooled Investment Accounts, LLC, its Managing Member

		
	By:	 	 /s/ David B. Weden, III

	Name: David B. Weden, III
	Title: Corporate Director, Investment Operations


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	MULTIPLE HOLDINGS, LLC
		
	By:	 	 /s/ Nathaniel S. Turner

	Name: Nathaniel S. Turner
	Title: Co-President


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

			
	INVESTORS:
	
	FIFTH AVENUE PRIVATE EQUITY 15 LLC
		
	By:	 	 /s/ Lisa M. Corcoran

	Name: Lisa M. Corcoran
	Title: Managing Director of Bessemer Trust Company, N.A., as Advisor


 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

	
	 INVESTORS:

	
	 /s/ Alexis Borisy

	 Alexis Borisy



 [Signature Page to IRA Amendment] 












 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first
above written. 
  

	
	INVESTORS:
	
	 /s/ Mark Murcko

	Mark Murcko


 [Signature Page to IRA Amendment]